Q32 Bio Inc.: 5%+ holders

As of November 10, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Q32 Bio Inc. The largest reported stake is Orbimed Advisors LLC's, at 13.9%. 22 filings are on record since February 13, 2026 (Schedule 13D/A, July 20, 2026).

Boxer Capital Management, LLC also filed stake reports on 1 other company ↓

Sell to companies like Q32 Bio Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-06 · Reporting person: Boxer Capital Management, LLC · Sole voting: 0 · Shared voting: 2,357,922 · Sole dispositive: 0 · Shared dispositive: 2,357,922 · SCHEDULE 13G/A, 2026-11-06
• Filed 2026-11-06 · Holder: Opaleye Management Inc. · Percent: 3.76% · SCHEDULE 13G/A
• Filing 2026-10-28 · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 2,204,979 · Sole dispositive: 0 · Shared dispositive: 2,205,390 · SCHEDULE 13G, 2026-10-28
• Filing 2026-10-09 · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 1,755,116 · Sole dispositive: 0 · Shared dispositive: 1,755,116 · SCHEDULE 13G, 2026-10-09
• Filed 2026-08-14 · Holder: Sirenia Capital Management LP · Percent: 0% · SCHEDULE 13G/A

Q32 Bio Inc. has 22 Schedule 13D or 13G filings on record since 2026-02-13. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Q32 Bio Inc. and the warning signs.

See Q32 Bio Inc.'s free Snapshot Watch Q32 Bio Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Q32 Bio Inc. and the records around it.

Q32 Bio Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Boxer Capital Management, LLC also filed stake reports on 1 other company: Surrozen, Inc./DE (Oct 2026)
• Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), Allogene Therapeutics, Inc. (Feb 2026)
• Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), GENERATION BIO CO. (May 2026)

Want the whole picture on Q32 Bio Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Q32 Bio Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Q32 Bio Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   22 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Q32 Bio Inc. by CUSIP 746964105 and gives its principal executive office as 830 Winter Street, Waltham, MA 02451 (SCHEDULE 13G/A, 2026-11-06).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-06-04

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.Boxer Capital Management, LLC, SCHEDULE 13G/A, 2026-11-06

3.76% Based on 29,769,466 shares of Common Stock outstanding as of August 3, 2026, as reported by Q32 Bio Inc. in its Form 10-Q filed with the SEC on August 5, 2026.Opaleye Management Inc., SCHEDULE 13G/A, 2026-11-06

Source of funds (Item 3)

Not applicable.Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-07-20

Purpose of Transaction (Item 4)

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-20; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Q32 Bio Inc.

Who owns Q32 Bio Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of Q32 Bio Inc.: Orbimed Advisors LLC (13.9%, Schedule 13D/A, filed 2026-07-20), Bvf Partners L P (9.99%, Schedule 13G, filed 2026-06-04), RA Capital Management, L.P. (9.8%, Schedule 13G, filed 2026-06-04), Boxer Capital Management, LLC (7.9%, Schedule 13G/A, filed 2026-11-06) and Bank Of America Corp (7.4%, Schedule 13G, filed 2026-10-28); 1 more is listed above.

Who are the largest shareholders of Q32 Bio Inc.?

By the share each holder's latest filing reports, the largest holders of Q32 Bio Inc. on this page are Orbimed Advisors LLC (13.9%), Bvf Partners L P (9.99%) and RA Capital Management, L.P. (9.8%).

When did Orbimed Advisors LLC buy into Q32 Bio Inc.?

The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-03-12, reporting 15.4%; its latest, Schedule 13D/A filed 2026-07-20, reports 13.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 22 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Q32 Bio Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Q32 Bio Inc. is mentioned again
• Find former Q32 Bio Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes